High-Dose Aflibercept Shows Promise for PCV With Fewer Injections
January 29, 2026 • Retinal Diseases Content Hub
The video features an interview with Tien Y. Wong, MD, PhD, Tsinghua University, about a post-hoc analysis from the PULSAR randomized trial evaluating high-dose aflibercept (8 mg) in patients with polypoidal choroidal vasculopathy (PCV). The discussion highlights that aflibercept 8 mg given at extended intervals showed similar improvements in visual acuity and anatomic outcomes compared with the standard 2-mg dose, suggesting it may be a viable monotherapy option for PCV with a reduced injection burden.
